Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mablink Bioscience
Lyon, Auvergne-Rhône-Alpes, Francemablink.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MBK-103, the lead ADC, has shown up to a 10-fold increase in therapeutic index in preclinical animal models and markedly improved tolerability via the hydrophilic PSARlink™ linker; no published clinical results yet.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodySmall molecule (ADC payloads, e.g., exatecan)
- Industry
- Biotech
02
Partnerships
Emergence Therapeutics (licensing of PSARlink™ for Nectin-4 ADC)
Beyond the preview
Go deeper on Mablink Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mablink Bioscience.